Investment Analysts’ Recent Ratings Updates for Gilead Sciences (GILD)

A number of firms have modified their ratings and price targets on shares of Gilead Sciences (NASDAQ: GILD) recently:

• 1/13/2026 – Gilead Sciences had its “outperform” rating reaffirmed by analysts at BMO Capital Markets.
• 1/13/2026 – Gilead Sciences had its price target lowered by analysts at Morgan Stanley from $151.00 to $150.00. They now have an “overweight” rating on the stock.
• 1/7/2026 – Gilead Sciences had its price target raised by analysts at Citigroup Inc. from $135.00 to $140.00. They now have a “buy” rating on the stock.
• 1/7/2026 – Gilead Sciences is now covered by analysts at UBS Group AG. They set a “buy” rating and a $145.00 price target on the stock.
• 1/3/2026 – Gilead Sciences was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 12/29/2025 – Gilead Sciences was given a new $135.00 price target on by analysts at Sanford C. Bernstein. They now have an “outperform” rating on the stock.
• 12/20/2025 – Gilead Sciences was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 12/15/2025 – Gilead Sciences had its “outperform” rating reaffirmed by analysts at Wolfe Research. They now have a $150.00 price target on the stock.
• 12/12/2025 – Gilead Sciences had its price target raised by analysts at Morgan Stanley from $147.00 to $151.00. They now have an “overweight” rating on the stock.
• 12/10/2025 – Gilead Sciences had its price target raised by analysts at HSBC Holdings plc from $110.00 to $133.00. They now have a “hold” rating on the stock.
• 12/10/2025 – Gilead Sciences had its price target raised by analysts at Wells Fargo & Company from $145.00 to $150.00. They now have an “overweight” rating on the stock.
• 12/4/2025 – Gilead Sciences was upgraded by analysts at UBS Group AG to a “hold” rating.
• 11/25/2025 – Gilead Sciences was given a new $135.00 price target on by analysts at BMO Capital Markets.
• 11/24/2025 – Gilead Sciences is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $140.00 price target on the stock.
• 11/21/2025 – Gilead Sciences had its price target raised by analysts at Mizuho from $131.00 to $140.00. They now have an “outperform” rating on the stock.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $124.83, for a total value of $1,248,300.00. Following the completion of the transaction, the chief executive officer owned 566,698 shares of the company’s stock, valued at $70,740,911.34. This represents a 1.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Kelly A. Kramer sold 2,805 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the completion of the sale, the director owned 1,339 shares in the company, valued at approximately $170,186.90. This represents a 67.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 130,757 shares of company stock valued at $16,205,752. 0.27% of the stock is owned by insiders.

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.